Arcutis Biotherapeutics Ownership | Who Owns Arcutis Biotherapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

Arcutis Biotherapeutics Ownership Summary


Arcutis Biotherapeutics is owned by 102.32% institutional investors, 1.78% insiders. Suvretta capital management is the largest institutional shareholder, holding 9.61% of ARQT shares. Polar Capital Biotech S Inc is the top mutual fund, with 5.00% of its assets in Arcutis Biotherapeutics shares.

ARQT Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockArcutis Biotherapeutics102.32%1.78%-4.10%
SectorHealthcare Stocks 50.47%12.28%37.25%
IndustryBiotech Stocks 49.08%12.05%38.87%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Suvretta capital management12.44M9.61%$326.10M
Blackrock funding, inc. /de10.55M8.15%$276.50M
Blackrock8.62M7.76%$80.19M
Frazier life sciences management9.87M7.63%$258.91M
Rubric capital management lp8.27M6.39%$216.88M
Vanguard group7.25M5.68%$210.65M
Polar capital6.61M5.11%$173.23M
State street5.82M4.50%$152.67M
Vanguard capital management4.99M3.86%$130.81M
Morgan stanley4.45M3.44%$116.71M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Pivotal bioventure partners investment advisor1.27M10.78%$33.18M
Suvretta capital management12.44M5.96%$326.10M
Frazier life sciences management9.87M5.64%$258.91M
Ally bridge group (ny)233.22K2.68%$4.40M
Rubric capital management lp8.27M1.99%$216.88M
Privium fund management b.v.399.37K1.92%$10.47M
Patient square capital lp370.00K1.50%$9.70M
Fishman jay a ltd/mi595.00K1.24%$15.60M
Tejara capital113.08K1.22%$2.97M
Orbimed advisors2.04M1.00%$53.54M

Top Buyers

HolderShares% AssetsChange
Orbimed advisors2.04M1.00%2.04M
Blackrock8.62M0.00%1.96M
D. e. shaw3.95M0.05%1.45M
Blackrock funding, inc. /de10.55M0.00%1.35M
Citadel advisors1.16M0.00%1.14M

Top Sellers

HolderShares% AssetsChange
Gilder gagnon howe1.31M0.36%-2.99M
Marshall wace, llp446.87K0.01%-1.98M
Paradigm biocapital advisors lp---1.47M
Perceptive advisors---1.36M
Driehaus capital management878.43K0.13%-1.35M

New Positions

HolderShares% AssetsChangeValue
Orbimed advisors2.04M1.00%2.04M$53.54M
Sixth street partners management company1.05M0.00%1.05M$27.56M
Norges bank392.30K0.00%392.30K$10.29M
Longaeva partners344.80K0.20%344.80K$9.04M
Balyasny asset management243.12K0.01%243.12K$6.37M

Sold Out

HolderChange
Twin peaks wealth advisors-7.00
Massmutual trust co fsb/adv-7.00
Advisory services network-19.00
Nelson, van denburg & campbell wealth management group-22.00
Stephens consulting-25.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 20262800.72%132,367,241-0.02%1020.98%137-5.52%10114.77%
Mar 31, 2026270-6.90%129,847,5480.58%1021.00%141-19.43%8611.69%
Dec 31, 2025127-48.79%34,362,908-72.69%260.27%72-40.98%38-54.22%
Sep 30, 202587-63.14%29,200,444-76.92%220.23%44-63.64%25-62.69%
Jun 30, 2025234-6.02%126,474,0751.16%991.01%120-6.25%66-20.48%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Polar Capital Biotech S Inc6.26M5.00%-197.81K
Vanguard US Total Market Shares ETF3.59M3.03%492.10K
Vanguard Total Stock Mkt Idx Inv3.57M2.85%33.08K
Vanguard Morn Total Stk Mkt Idx Investor3.57M2.85%33.08K
iShares Russell 2000 ETF2.88M2.29%-51.17K
State Street® SPDR® S&P® Biotech ETF2.86M2.28%6.57K
Jennison Health Sciences Equity2.27M1.90%-
PGIM Jennison Health Sciences Z2.27M1.89%-
SPDR® S&P Biotech ETF1.88M1.57%4.20K
American Century U.S. Small Cap Growth1.47M1.17%351.83K

Recent Insider Transactions


DateNameRoleActivityValue
Aug 11, 2026Burnett Patrick See RemarksSell$220.13K
Aug 12, 2026Burnett Patrick See RemarksSell$174.77K
Aug 03, 2026Burnett Patrick See RemarksSell$24.94K
Aug 03, 2026Matsuda Masaru See RemarksSell$32.12K
Aug 03, 2026Watanabe Todd See RemarksSell$114.26K

Insider Transactions Trends


DateBuySell
2026 Q3-6
2026 Q2-12
2026 Q1-26
2025 Q4-32
2025 Q3-15

ARQT Ownership FAQ


Who Owns Arcutis Biotherapeutics?

Arcutis Biotherapeutics shareholders are primarily institutional investors at 102.32%, followed by 1.78% insiders and -4.10% retail investors. The average institutional ownership in Arcutis Biotherapeutics's industry, Biotech Stocks , is 49.08%, which Arcutis Biotherapeutics exceeds.

Who owns the most shares of Arcutis Biotherapeutics?

Arcutis Biotherapeutics’s largest shareholders are Suvretta capital management (12.44M shares, 9.61%), Blackrock funding, inc. /de (10.55M shares, 8.15%), and Blackrock (8.62M shares, 7.76%). Together, they hold 25.53% of Arcutis Biotherapeutics’s total shares outstanding.

Does Blackrock own Arcutis Biotherapeutics?

Yes, BlackRock owns 7.76% of Arcutis Biotherapeutics, totaling 8.62M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 80.19M$. In the last quarter, BlackRock increased its holdings by 1.96M shares, a 29.49% change.

Who is Arcutis Biotherapeutics’s biggest shareholder by percentage of total assets invested?

Pivotal bioventure partners investment advisor is Arcutis Biotherapeutics’s biggest shareholder by percentage of total assets invested, with 10.78% of its assets in 1.27M Arcutis Biotherapeutics shares, valued at 33.18M$.

Who is the top mutual fund holder of Arcutis Biotherapeutics shares?

Polar Capital Biotech S Inc is the top mutual fund holder of Arcutis Biotherapeutics shares, with 5.00% of its total shares outstanding invested in 6.26M Arcutis Biotherapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools